Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03628651 · ClinicalTrials.gov registry record
Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma
A clinical trial, sponsored by Exact Sciences Corporation.
- Completed
- Registry status
- 2,150
- Enrollment target
NCT03628651: Completed study, sponsored by Exact Sciences Corporation.
NCT03628651 is a clinical trial that has completed, run by Exact Sciences Corporation. The registered enrollment target is 2,150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03628651 has completed, sponsored by Exact Sciences Corporation.
- COMPLETED
- Registry status
- 2,150 participants
- Enrollment target
Study Summary
The primary objective of this study is to obtain de-identified, clinically-characterized whole blood specimens for use in developing and evaluating the performance of new biomarker assays for detection of hepatocellular carcinoma (HCC).
Primary Outcome
Biomarkers under evaluation include differential methylation of nucleic acids and altered expression of proteins in blood from subjects with HCC compared to those without (but are at risk of developing the disease so are under surveillance)
Interventions
- OTHER Blood Sample Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,150 participants |
| Start Date | 2018-04-02 |
| Est. Completion | 2020-03-11 |
What the finished NCT03628651 record still lists
NCT03628651 is an observational study that tracks outcomes without assigning an intervention. Its 2,150 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Blood Sample Collection is the first listed.
NCT03628651 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03628651 about?
NCT03628651 is a clinical study titled "Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma". The primary objective of this study is to obtain de-identified, clinically-characterized whole blood specimens for use in developing and evaluating the performance of new biomarker assays for detection of hepatocellular carcinoma (HCC).
What is the current status of trial NCT03628651?
This trial is currently completed. The enrollment target is 2,150 participants. The study started on 2018-04-02. Estimated completion is 2020-03-11.
What interventions are being tested in trial NCT03628651?
The interventions under investigation include: Blood Sample Collection (OTHER).
Who is sponsoring clinical trial NCT03628651?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06783335 · 2,150 participants
Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure
- NCT05805709 · 2,145 participants · NA
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
- NCT06598475 · 2,142 participants · NA
Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
- NCT05742178 · 2,160 participants · NA
NYC Cancer Outreach Network in Neighborhoods for Equity and Community Translation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI